[1] |
岳晓丽, 龚向东, 滕菲, 等. 2008—2015年中国性病监测点生殖道沙眼衣原体感染流行特征分析[J]. 中华皮肤科杂志, 2016,49(5):308⁃313. doi: 10.3760/cma.j.issn.0412⁃4030.2016.05.002.<br />
|
[2] |
Lee YS, Lee KS. Chlamydia and male lower urinary tract diseases[J]. Korean J Urol, 2013,54(2):73⁃77. doi: 10.4111/kju.2013.54. 2.73.<br />
|
[3] |
Lewis ME, Belland RJ, AbdelRahman YM, et al. Morphologic and molecular evaluation of Chlamydia trachomatis growth in human endocervix reveals distinct growth patterns[J]. Front Cell Infect Microbiol, 2014,4:71. doi: 10.3389/fcimb.2014.00071.<br />
|
[4] |
Schoborg RV. Chlamydia persistence ⁃⁃ a tool to dissect chlamydia⁃⁃host interactions[J]. Microbes Infect, 2011,13(7):649⁃662. doi: 10.1016/j.micinf.2011.03.004.<br />
|
[5] |
Pirbhai M, Dong F, Zhong Y, et al. The secreted protease factor CPAF is responsible for degrading pro⁃apoptotic BH3⁃only proteins in Chlamydia trachomatis⁃infected cells[J]. J Biol Chem, 2006,281(42):31495⁃31501. doi: 10.1074/jbc.M602796200.<br />
|
[6] |
Rajalingam K, Sharma M, Lohmann C, et al. Mcl⁃1 is a key regulator of apoptosis resistance in Chlamydia trachomatis⁃infected cells[J/OL]. PLoS One, 2008,3(9):e3102. doi: 10.1371/journal.pone.0003102.<br />
|
[7] |
Xiao Y, Zhong Y, Greene W, et al. Chlamydia trachomatis infection inhibits both Bax and Bak activation induced by staurosporine[J]. Infect Immun, 2004,72(9):5470⁃5474. doi: 10.1128/IAI.72.9.5470⁃5474.2004.<br />
|
[8] |
Rajalingam K, Sharma M, Paland N, et al. IAP⁃IAP complexes required for apoptosis resistance of C. trachomatis⁃infected cells[J/OL]. PLoS Pathog, 2006,2(10):e114. doi: 10.1371/journal.ppat. 0020114.<br />
|
[9] |
Xue Y, Zheng H, Mai Z, et al. An in vitro model of azithromycin⁃induced persistent Chlamydia trachomatis infection[J]. FEMS Microbiol Lett, 2017,364(14). doi: 10.1093/femsle/fnx145.<br />
|
[10] |
黄敏, 李建红, 段行武, 等. 生殖道沙眼衣原体持续性感染研究进展[J].中华皮肤科杂志, 2013,46(8):607⁃609. doi: 10.3760/cma.j.issn.0412⁃4030.2013.08.026.<br />
|
[11] |
Zheng H, Xue Y, Bai S, et al. Association of the in vitro susceptibility of clinical isolates of Chlamydia trachomatis with serovar and duration of antibiotic exposure[J]. Sex Transm Dis, 2015,42(3):115⁃119. doi: 10.1097/OLQ.0000000000000241.<br />
|
[12] |
Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta⁃analysis of randomized clinical trials[J]. Sex Transm Dis, 2002,29(9):497⁃502.<br />
|
[13] |
Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta⁃analysis of randomized controlled trials[J]. Clin Infect Dis, 2014,59(2):193⁃205. doi: 10.1093/cid/ciu220.<br />
|
[14] |
Ying S, Pettengill M, Ojcius DM, et al. Host⁃cell survival and death during chlamydia infection[J]. Curr Immunol Rev, 2007,3(1):31⁃40. doi: 10.2174/157339507779802179.<br />
|
[15] |
Dean D, Powers VC. Persistent Chlamydia trachomatis infections resist apoptotic stimuli[J]. Infect Immun, 2001,69(4):2442⁃2447. doi: 10.1128/IAI.69.4.2442⁃2447.2001.<br />
|
[16] |
Caldwell HD, Wood H, Crane D, et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates[J]. J Clin Invest, 2003,111(11):1757⁃1769. doi: 10.1172/JCI17993.<br />
|
[17] |
Ying S, Fischer SF, Pettengill M, et al. Characterization of host cell death induced by Chlamydia trachomatis[J]. Infect Immun, 2006,74(11):6057⁃6066. doi: 10.1128/IAI.00760⁃06.<br />
|